Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Evotec SE    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report  
Real-time Quote. Real-time Tradegate - 07/17 03:59:22 pm
25.55 EUR   -0.12%
07/16EVOTEC : expands its iPSC discovery platform
AQ
07/15EVOTEC : Expands its ipsc discovery platform
EQ
07/12EVOTEC SE : Notification and public disclosure of transactions by persons
EQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Evotec : receives $ 23.8 m grant to join the global fight against tuberculosis

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/11/2019 | 10:05am EDT

Hamburg - Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the company has entered into a five-year partnership with the Bill & Melinda Gates Foundation to discover new treatment regimens that better address tuberculosis ('TB'), a severe global health burden and one of the leading causes of death due to infectious diseases worldwide.

The current standard treatment regimen for TB consists of a minimum of 6 months of treatment with 4 drugs administered under direct observation, but treatment is much longer when TB is drug resistant.

Evotec will receive a grant of approximately $ 23.8 m for a period of up to 5 years from the foundation. The main objective of the grant is to generate standardised, high-quality pre-clinical data to support novel regimen selection and development. The regimen should be safer, shorter in duration and more efficacious than the current standard of care. With this new grant from the Bill & Melinda Gates Foundation, Evotec has been selected once more as an essential partner for charities and foundations, such as CHDI, The Michael J. Fox Foundation and the Mark Foundation, in their research and development efforts to address complex, rare and difficult diseases.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: 'We are honoured to join with The Bill & Melinda Gates Foundation to fight tuberculosis, one of the world's most deadly infectious diseases. With our contributions of industrialised, high quality infrastructure and innovative methodology, we are confident that this combined international effort is the best possible starting point to bring huge benefits to the large number of patients who suffer from TB around the globe.'

About Tuberculosis

Tuberculosis ('TB') is an airborne infectious disease most commonly caused by the Mycobacterium tuberculosis ('MTB') bacteria. It usually affects the lungs but can spread to other parts of the body as well. Tuberculosis is among the leading killers by infectious disease and is one of the ten most common causes of death worldwide. In 2017, 10 million people fell ill with TB, and 1.6 million died from the disease. The disease disproportionally affects young children, with an estimated 1 million children falling ill with TB and 230,000 of them dying in 2017. TB is also a leading cause of death for people living with HIV, with 300,000 of such patients dying in (2017). Multidrug-resistant TB ('MDR-TB') remains a public health crisis and a health security threat. The World Health Organization ('WHO') estimates that in 2017 there were 558,000 new cases with resistance to rifampicin, the most effective first-line drug, 82% of which were MDR-TB. As a result of years of inadequate diagnosis and treatment, these types of drug-resistant TB are more difficult and costly to treat, highlighting the urgent need for new, better, faster-acting treatments.

ABOUT THE BILL & MELINDA GATES FOUNDATION

Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. In developing countries, it focuses on improving people's health and giving them the chance to lift themselves out of hunger and extreme poverty. In the United States, it seeks to ensure that all people-especially those with the fewest resources-have access to the opportunities they need to succeed in school and life. Based in Seattle, Washington, the foundation is led by CEO Sue Desmond-Hellmann and Co-chair William H. Gates Sr., under the direction of Bill and Melinda Gates and Warren Buffett.

Contact:

Tel: +1.206.726.7179

Email: Kitty.Harding@gatesfoundation.org

FORWARD LOOKING STATEMENTS

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EVOTEC SE
07/16EVOTEC : expands its iPSC discovery platform
AQ
07/15EVOTEC : Expands its ipsc discovery platform
EQ
07/12EVOTEC SE : Notification and public disclosure of transactions by persons
EQ
07/08Eurofins to slow pace of M&A, expand in emerging markets
RE
07/08EVOTEC : and venture capital consortium form 'Breakpoint Therapeutics GmbH'
AQ
07/08EVOTEC : And venture capital consortium form 'breakpoint therapeutics gmbh'
EQ
07/04EVOTEC : completes acquisition of Just Biotherapeutics
AQ
07/03EVOTEC SE : Notification and public disclosure of transactions by persons
EQ
07/03EVOTEC : Completes acquisition of just biotherapeutics
EQ
06/28EVOTEC SE : Release according to Article 41 of the WpHG [the German Securities T..
EQ
More news
Financials (EUR)
Sales 2019 417 M
EBIT 2019 76,6 M
Net income 2019 55,3 M
Finance 2019 64,1 M
Yield 2019 -
P/E ratio 2019 64,1x
P/E ratio 2020 64,4x
EV / Sales2019 9,03x
EV / Sales2020 8,11x
Capitalization 3 828 M
Chart EVOTEC SE
Duration : Period :
Evotec SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 26,20  €
Last Close Price 25,56  €
Spread / Highest target 29,1%
Spread / Average Target 2,50%
Spread / Lowest Target -21,8%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Craig L. Johnstone Chief Operating Officer & Member-Management Board
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC SE47.31%4 217
IQVIA HOLDINGS INC34.78%31 409
LONZA GROUP32.31%25 111
CELLTRION, INC.--.--%20 827
INCYTE CORPORATION25.62%17 419
EXACT SCIENCES CORPORATION82.17%15 001